New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 21, 2014
10:01 EDTJNJCordis receives CE mark for Renlane to treat resistant hypertension
Cordis, part of the Johnson & Johnson Family of Companies, announced that it has received European CE Mark for its Renlane Renal Denervation System for the treatment of patients with resistant hypertension and has completed the first successful cases in Europe. The Renlane System consists of a unique, helical shaped, irrigated, multi-electrode ablation catheter with a multi-channel radiofrequency ablation system. The first successful cases were performed by Hannes Reuter, M.D., at the University of Cologne Hospital in Germany. The treated patients were diagnosed with resistant hypertension and had systolic blood pressures greater than or equal to 160 mm Hg, despite undergoing traditional drug therapy with three or more anti-hypertensive medications. All procedures were performed successfully and patients were discharged after one day.
News For JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent JNJ news | >>
February 26, 2015
09:41 EDTJNJHospira launches generic Remicade, WSJ says
Subscribe for More Information
08:03 EDTJNJJohnson & Johnson forms new health and wellness platform
Subscribe for More Information
06:52 EDTJNJPharmacyclics downgraded to Hold from Buy at WallachBeth
Subscribe for More Information
February 25, 2015
14:47 EDTJNJPharmacyclics could fetch as much as $19B in sale, FT says
Pharmacyclics (PCYC) is considering a sale that could fetch as much as $19B, reported Financial Times, citing people familiar with the matter who said Johnson & Johnson (JNJ) is exploring a potential deal for the company. The Fly notes that Bloomberg had a similar report, but its report said Pharmacyclics could fetch $17B-$18B in a sale. Reference Link
14:10 EDTJNJPharmacyclics downgraded to Hold on lack of upside at Deutsche Bank
Subscribe for More Information
12:54 EDTJNJPharmacyclics exploring options including sale, Bloomberg reports
According to sources, Pharmacyclics (PCYC), which develops cancer treatments, is currently exploring options, Bloomberg reports. One option may include a sale of the company, and the sources say Johnson & Johnson (JNJ) and Novartis (NVS) have expressed interest in the company. Pharmacyclics could fetch $17B-$18B in a sale, the sources add. Reference Link
12:53 EDTJNJPharmacyclics weighing sale to U.S. drugmaker, Bloomberg reports
Subscribe for More Information
February 22, 2015
12:51 EDTJNJJ&J considers Cordis sale with Cardinal the leading suitor, Bloomberg says
Subscribe for More Information
February 20, 2015
17:31 EDTJNJJ&J considering sale of Cordis with Cardinal the leading suitor, Bloomberg says
Subscribe for More Information
16:03 EDTJNJOptions Update; February 20, 2015
Subscribe for More Information
09:38 EDTJNJActive equity options trading on open
Subscribe for More Information
07:23 EDTJNJAbbVie replaces Pfizer as top global pharma pick at Jefferies
Subscribe for More Information
February 18, 2015
16:46 EDTJNJOn The Fly: Closing Wrap
Subscribe for More Information
12:36 EDTJNJAnalysts applaud cheaper than expected Boston Scientific settlement
Subscribe for More Information
12:31 EDTJNJOn The Fly: Midday Wrap
Subscribe for More Information
07:41 EDTJNJSettlement 'a big win' for Boston Scientific, says Bernstein
Subscribe for More Information
07:12 EDTJNJBoston Scientific settlement should remove overhang, says Stifel
Subscribe for More Information
07:09 EDTJNJBoston Scientific payment to J&J well below expectations, says Piper Jaffray
Subscribe for More Information
February 17, 2015
16:29 EDTJNJ Boston Scientific announces settltement of merger agreement lawsuit
Subscribe for More Information
07:04 EDTJNJGTx names Robert Wills as executive chairman
Subscribe for More Information
1 | 2 | all recent JNJ news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use